DDInter1619 DDInter1925
Ropinirole, also known as _ReQuip_, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome [FDA label],. It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA [FDA label] for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary moderate to severe restless legs syndrome. In 2008, the extended-release capsules of ropinirole were approved, allowing for less frequent dosing, therefore increased compliance, and offering a similar side effect profile and efficacy to previous formulations of ropinirole.
Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program.
Ropinirole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) upregulates {v} (Gene) IKZF1
IKZF1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) downregulates {v} (Gene) HAT1
HAT1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) upregulates {v} (Gene) GTF2A2
GTF2A2 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) causes {v} (Side Effect) Eosinophilia
Eosinophilia {u} (Side Effect) is caused by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etoricoxib
Etoricoxib {u} (Compound) resembles {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) upregulates {v} (Gene) IKZF1
IKZF1 {u} (Gene) is regulated by {v} (Gene) BRAF
BRAF {u} (Gene) is bound by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) downregulates {v} (Gene) DECR1
DECR1 {u} (Gene) is regulated by {v} (Gene) SATB1
SATB1 {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ropinirole {u} (Compound) upregulates {v} (Gene) GTF2A2
GTF2A2 {u} (Gene) is regulated by {v} (Gene) PRR15L
PRR15L {u} (Gene) is upregulated by {v} (Compound) Vemurafenib
Ropinirole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Ropinirole (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is upregulated by Vemurafenib (Compound)
Ropinirole (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is upregulated by Vemurafenib (Compound)
Ropinirole (Compound) downregulates HAT1 (Gene) and HAT1 (Gene) is downregulated by Vemurafenib (Compound)
Ropinirole (Compound) upregulates GTF2A2 (Gene) and GTF2A2 (Gene) is downregulated by Vemurafenib (Compound)
Ropinirole (Compound) causes Eosinophilia (Side Effect) and Eosinophilia (Side Effect) is caused by Vemurafenib (Compound)
Ropinirole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound) and Etoricoxib (Compound) resembles Vemurafenib (Compound)
Ropinirole (Compound) upregulates IKZF1 (Gene) and IKZF1 (Gene) is regulated by BRAF (Gene) and BRAF (Gene) is bound by Vemurafenib (Compound)
Ropinirole (Compound) downregulates DECR1 (Gene) and DECR1 (Gene) is regulated by SATB1 (Gene) and SATB1 (Gene) is upregulated by Vemurafenib (Compound)
Ropinirole (Compound) upregulates GTF2A2 (Gene) and GTF2A2 (Gene) is regulated by PRR15L (Gene) and PRR15L (Gene) is upregulated by Vemurafenib (Compound)